SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones In 2024
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group, Inc. has provided updates on its corporate activities and outlined key milestones for 2024. These include interim analysis of the Phase 3 REGAL study of Galinpepimut-S in Acute Myeloid Leukemia (AML) patients expected in Q1 2024, topline data from a Phase 2a study of SLS009 in relapsed/refractory AML patients also expected in Q1 2024, and topline data from a Phase 1b/2 study in relapsed/refractory Peripheral T-cell Lymphoma patients expected in the first half of 2024.
January 03, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences Group, Inc. has announced upcoming milestones for 2024, which could significantly impact the company's stock price if the results are positive, particularly the interim analysis of the Phase 3 REGAL study and topline data from the Phase 2a SLS009 study.
The announcement of upcoming milestones for SELLAS's key clinical studies is likely to generate investor interest and optimism, especially if the data from these studies is positive. This could lead to an increase in the stock price in the short term as investors anticipate potential breakthroughs in the company's cancer treatments.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100